Compare FMN & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMN | BMEA |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.0M | 87.7M |
| IPO Year | N/A | 2021 |
| Metric | FMN | BMEA |
|---|---|---|
| Price | $11.16 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.71 |
| AVG Volume (30 Days) | 22.8K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.09 | $0.87 |
| 52 Week High | $11.31 | $4.59 |
| Indicator | FMN | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 60.49 |
| Support Level | $11.05 | $1.23 |
| Resistance Level | $11.15 | $1.37 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 94.37 | 74.65 |
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.